ImmunoGen Update (2-22-13)

 Comments Off on ImmunoGen Update (2-22-13)
Feb 222013
 
ImmunoGen Update (2-22-13)

Roche received FDA approval for IMGN’s T-DM1 (Kadcyla) for the treatment of late-stage metastatic breast cancer patients who fail to respond to Herceptin and taxol.  While this was a widely expected approval, it represents a significant milestone for IMGN as this is their first drug approval. The company will receive a $10.5 million milestone payment […]

ImmunoGen Update (1-18-13)

 Comments Off on ImmunoGen Update (1-18-13)
Jan 182013
 
ImmunoGen Update (1-18-13)

With T-DM1 FDA approval nearing the goal line – the PDUFA date is February 26 – ImmunoGen will join the ranks of commercially successful biotech companies, a major achievement. While it is widely known that the royalty rate IMGN will receive from partner Roche (~3%) is unlikely to lead the company to major profitability, regulatory […]

ImmunoGen Update (1-04-13)

 Comments Off on ImmunoGen Update (1-04-13)
Jan 042013
 
ImmunoGen Update (1-04-13)

ImmunoGen has announced that Amgen has licensed the exclusive right to use the Company’s TAP technology to develop anticancer therapeutics to a third target, which is undisclosed.  Amgen licensed rights for two other targets in 2009 and has two compounds in clinical testing under those licenses. “We’re pleased with the interest major healthcare companies are […]